Ossiam Has $5.23 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ossiam lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,429 shares of the biopharmaceutical company’s stock after buying an additional 302 shares during the period. Ossiam’s holdings in Regeneron Pharmaceuticals were worth $5,225,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of REGN. Vanguard Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after acquiring an additional 91,956 shares in the last quarter. Capital World Investors grew its position in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after purchasing an additional 23,146 shares in the last quarter. Putnam Investments LLC increased its stake in Regeneron Pharmaceuticals by 2.1% in the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after buying an additional 24,329 shares during the last quarter. Norges Bank bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $932,571,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 3.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 620,616 shares of the biopharmaceutical company’s stock worth $545,081,000 after buying an additional 22,558 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $1,229.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, June 24th. TD Cowen increased their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday. Piper Sandler raised their target price on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $1,040.00 to $1,180.00 and gave the stock a “buy” rating in a research report on Thursday, July 18th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,074.95.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $3.33 during trading on Thursday, hitting $1,064.19. The company had a trading volume of 525,090 shares, compared to its average volume of 468,509. The firm has a market capitalization of $117.26 billion, a P/E ratio of 31.44, a price-to-earnings-growth ratio of 2.19 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a one year low of $723.56 and a one year high of $1,106.16. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The stock’s 50-day moving average price is $1,031.92 and its 200 day moving average price is $975.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The company had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.02 EPS for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Leonard S. Schleifer sold 22,830 shares of the company’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the completion of the sale, the chief executive officer now directly owns 466,877 shares in the company, valued at approximately $457,179,964.71. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the transaction, the chief executive officer now owns 408,200 shares in the company, valued at approximately $399,729,850. The disclosure for this sale can be found here. Insiders sold 65,074 shares of company stock valued at $64,546,123 over the last quarter. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.